MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
CRISPR Therapeutics AG Balance Sheet 2011-2026 | CRSP
Annual Balance Sheet CRISPR Therapeutics AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-141 M | -74.6 M | -151 M | 32.1 M | -698 M | - | -891 M | -457 M | -240 M | -316 M | -118 M | -945 K | - | - | - |
Long Term Debt |
188 M | 206 M | 223 M | 228 M | 213 M | - | - | - | - | - | 38.3 M | - | - | - | - |
Long Term Debt Current |
18.6 M | 17.3 M | 15.6 M | 15.8 M | 12.2 M | 11.4 M | 8.49 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 70.2 M | 69.1 M | 69 M | 90.1 M | 178 M | 6.36 M | - | - | - |
Total Current Liabilities |
149 M | 87.8 M | 109 M | 121 M | 120 M | 94.3 M | 57.1 M | 27.7 M | 14.5 M | 22 M | - | - | - | - | - |
Total Liabilities |
343 M | 310 M | 347 M | 368 M | 352 M | 164 M | 127 M | 96.8 M | 83.5 M | 112 M | 189 M | 8.5 M | - | - | - |
Deferred Revenue |
15.8 M | 3.84 M | 4.1 M | - | 1.01 M | 2.34 M | 960 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.95 B | -1.37 B | -1 B | -846 M | -196 M | -574 M | -225 M | -292 M | -125 M | -57.1 M | -33.9 M | -8.4 M | - | - | - |
Total Assets |
2.27 B | 2.24 B | 2.23 B | 2.24 B | 2.75 B | 1.83 B | 1.07 B | 489 M | 271 M | 345 M | 159 M | 1.53 M | - | - | - |
Cash and Cash Equivalents |
348 M | 298 M | 389 M | 212 M | 923 M | 1.17 B | 944 M | 457 M | 240 M | 316 M | 156 M | 945 K | - | - | - |
Book Value |
1.92 B | 1.93 B | 1.88 B | 1.88 B | 2.4 B | 1.66 B | 939 M | 392 M | 188 M | 233 M | -29.1 M | -6.97 M | - | - | - |
Total Shareholders Equity |
1.92 B | 1.93 B | 1.88 B | 1.88 B | 2.4 B | 1.66 B | 939 M | 392 M | 188 M | 233 M | -29.1 M | -6.97 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet CRISPR Therapeutics AG
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
193 M | 197 M | 202 M | 206 M | 211 M | 215 M | 219 M | 223 M | 227 M | 230 M | 225 M | 228 M | 231 M | 234 M | 228 M | 213 M | 193 M | 175 M | 49.4 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 44 M | 44 M | 44 M | 44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
329 M | 319 M | 337 M | 310 M | 316 M | 359 M | 355 M | 347 M | 359 M | 381 M | 389 M | 368 M | 399 M | 373 M | 361 M | 352 M | 309 M | 296 M | 152 M | 164 M | 164 M | 164 M | 164 M | 127 M | 127 M | 127 M | 127 M | 96.8 M | 96.8 M | 96.8 M | 96.8 M | 83.5 M | 83.5 M | 83.5 M | 83.5 M | 112 M | 112 M | 112 M | 112 M | 124 M | 124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.3 M | 2.13 M | 3.02 M | 3.84 M | 4.48 M | 4.76 M | 4.07 M | 4.1 M | 3.5 M | - | - | - | - | - | - | 1.01 M | 1.56 M | 2.07 M | 1.8 M | 2.34 M | 2.34 M | 2.34 M | 2.34 M | 960 K | 960 K | 960 K | 960 K | 102 K | 102 K | - | - | - | - | - | - | - | 63.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.82 B | -1.71 B | -1.5 B | -1.37 B | -1.33 B | -1.24 B | -1.12 B | -1 B | -1.09 B | -977 M | -899 M | -846 M | -736 M | -561 M | -375 M | -196 M | -54.7 M | 72.5 M | -687 M | -574 M | -574 M | -574 M | -574 M | -225 M | -225 M | -225 M | -225 M | -292 M | -292 M | -292 M | -292 M | -125 M | -125 M | -125 M | -125 M | -57.1 M | -57.1 M | -57.1 M | -57.1 M | -33.9 M | -33.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.25 B | 2.03 B | 2.17 B | 2.24 B | 2.26 B | 2.34 B | 2.44 B | 2.23 B | 2.09 B | 2.2 B | 2.24 B | 2.24 B | 2.35 B | 2.46 B | 2.61 B | 2.75 B | 2.82 B | 2.9 B | 1.96 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 489 M | 489 M | 489 M | 489 M | 271 M | 271 M | 271 M | 271 M | 345 M | 345 M | 345 M | 345 M | 159 M | 159 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
286 M | 194 M | 235 M | 298 M | 226 M | 484 M | 707 M | 389 M | 528 M | 445 M | 344 M | 212 M | 494 M | 497 M | 684 M | 923 M | 1.01 B | 1.65 B | 1.13 B | 1.17 B | 1.17 B | 1.17 B | 1.17 B | 944 M | 944 M | 944 M | 944 M | 457 M | 457 M | 457 M | 457 M | 240 M | 254 M | 272 M | 289 M | 316 M | 316 M | 316 M | 316 M | 156 M | 156 M | - | - | 945 K | - | - | - | 361 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.92 B | 1.71 B | 1.83 B | 1.93 B | 1.94 B | 1.98 B | 2.08 B | 1.88 B | 1.73 B | 1.82 B | 1.85 B | 1.88 B | 1.95 B | 2.09 B | 2.24 B | 2.4 B | 2.51 B | 2.6 B | 1.81 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 939 M | 939 M | 939 M | 939 M | 392 M | 392 M | 392 M | 392 M | 188 M | 188 M | 188 M | 188 M | 233 M | 233 M | 233 M | 233 M | 35.4 M | 35.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.92 B | 1.71 B | 1.83 B | 1.93 B | 1.94 B | 1.98 B | 2.08 B | 1.88 B | 1.73 B | 1.82 B | 1.85 B | 1.88 B | 1.95 B | 2.09 B | 2.24 B | 2.4 B | 2.51 B | 2.6 B | 1.81 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 939 M | 939 M | 939 M | 939 M | 392 M | 392 M | 392 M | 392 M | 188 M | 188 M | 188 M | 188 M | 233 M | 233 M | 233 M | 233 M | -29.1 M | -29.1 M | - | - | -6.97 M | - | - | - | -581 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of CRISPR Therapeutics AG, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Germany
USA
China
Britain
Canada
France
Israel
Russia
Australia
Cayman-islands
